Market Size of Global G-Protein Coupled Receptors (GPCR) Industry
Study Period | 2021 - 2029 |
Market Size (2024) | USD 6.11 Billion |
Market Size (2029) | USD 8.58 Billion |
CAGR (2024 - 2029) | 7.01 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
G-protein Coupled Receptors Market Analysis
The Global G-Protein Coupled Receptors Market size is estimated at USD 6.11 billion in 2024, and is expected to reach USD 8.58 billion by 2029, growing at a CAGR of 7.01% during the forecast period (2024-2029).
- The SARS-CoV-2 virus enters the body through the respiratory tract epithelium, mainly the lungs, and spreads to other organs through hematogenous expansion, causing multiorgan injury. The viral vector loading targeting Na+/H+ exchanger regulatory factor 1 (NHERF1) and -arrestin can disrupt the assembly of certain sensory G-protein coupled receptor (GPCR) signalosomes, resulting in disordered cellular responses such as loss of smell and taste.
- This has led researchers to investigate the role of GPCRs in alleviating COVID-19 symptoms. GPCR-targeted drugs have shown potential in reducing the pathogenic symptoms associated with COVID-19, leading to market growth during the initial phase of the pandemic. However, as the pandemic has subsided, research and development activities have slowed down, causing the studied market to lose some traction, but it is expected to have stable growth during the forecast period.
- The G-protein coupled receptors market is anticipated to be driven by the increasing number of cancer cases, cardiovascular infections, and respiratory issues. GPCRs play a crucial role in the development of new medications. According to the American Heart Association's 2021 Journal, more than 130 million adults in the United States are expected to have some type of heart disease by 2035. The Heart and Stroke Foundation of Canada's February 2022 report states that 750,000 people are living with heart failure in Canada, and 100,000 people are diagnosed with this incurable condition each year.
- A press release by Septerna in 2021 mentioned that GPCRs are one of the most prolific drug targets, representing approximately one-third of all approved drugs, and currently extend across all major disease areas. Septerna launched a financing of USD 100 million in January 2022 to advance its emerging pipeline of novel GPCR-targeted drug programs spanning multiple therapeutic areas.
- In April 2021, Tectonic Therapeutic raised USD 80 million in financing to unlock the full potential of GPCR-targeted therapies with biologics. These activities by market players are likely to contribute to market growth over the forecast period. Furthermore, strategic collaborations among market players are expected to boost market growth.
- For example, in December 2022, Sosei Heptares and Eli Lilly launched a drug discovery collaboration to discover, develop, and commercialize small compounds that modify novel G protein-coupled receptor (GPCR) targets related to diabetes and metabolic disorders. In August 2022, Sosei Group Corporation and AbbVie announced a new drug development cooperation and option-to-license agreement to identify, develop, and market small compounds modulating novel G protein-coupled receptor (GPCR) targets linked to neurological illness.
- Despite the market's potential for growth, the high cost involved in maintaining GPCR cell lines and the complexity of the GPCR signaling system may impede market growth.
G-protein Coupled Receptors Industry Segmentation
As per the scope of the report, G-protein coupled receptor (GPCR) is a protein located in the cell membrane that binds extracellular substances and transmits signals from these substances to an intracellular molecule called a G protein (guanine nucleotide-binding protein). GPCRs are found in the cell membranes of a wide range of organisms, including mammals, plants, microorganisms, and invertebrates.
The g-protein coupled receptors (GPCR) market is segmented by assay type (calcium level detection assays, radioligand binding and GTPγS functional assays, cAMP assays and cGMP assays, β-arrestin functional assays, reporter gene assays, and other assay types), application (cardiovascular system, central nervous system (CNS), oncology and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
By Assay Type | |
Calcium Level Detection Assays | |
Radioligand Binding and GTPγS Functional Assays | |
cAMP Assays and cGMP Assays | |
β-Arrestin Functional Assays | |
Reporter Gene Assays | |
Other Assay Types |
By Application | |
Cardiovascular System | |
Central Nervous System (CNS) | |
Oncology | |
Other Applications |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global G-Protein Coupled Receptors (GPCR) Market Size Summary
The G-protein coupled receptors (GPCR) market is poised for steady growth, driven by their critical role in drug development across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. GPCRs are integral to the development of new medications, with a significant portion of approved drugs targeting these receptors. The market's expansion is supported by increasing cancer cases and cardiovascular conditions, which necessitate advanced treatments. Despite the initial boost from COVID-19 research, the market has stabilized, with ongoing investments and collaborations among key players like Septerna and Tectonic Therapeutics aiming to unlock the potential of GPCR-targeted therapies. However, challenges such as high costs and the complexity of GPCR signaling systems may hinder growth.
North America is expected to be a significant contributor to the market's growth, fueled by its advanced biotechnology and biopharmaceutical sectors. The region's increasing burden of chronic diseases, particularly cancer and cardiovascular conditions, drives demand for innovative therapies. Strategic collaborations and investments in research are further propelling market advancements. Companies are actively expanding their portfolios through mergers, acquisitions, and partnerships, with notable players like Thermo Fisher Scientific and Merck KGaA leading the charge. These efforts, coupled with government support and technological advancements, are anticipated to sustain the market's growth trajectory over the forecast period.
Global G-Protein Coupled Receptors (GPCR) Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Demand for GPCR Assays in Drug Discovery Studies
-
1.2.2 Wide Range Applications of GPCRs in the Treatment for Various Medical Conditions
-
1.2.3 Increasing Prevalence of Chronic Diseases
-
-
1.3 Market Restraints
-
1.3.1 Challenges with the Purification of GPCRs
-
1.3.2 Complexity of the GPCR Signalling System
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Assay Type
-
2.1.1 Calcium Level Detection Assays
-
2.1.2 Radioligand Binding and GTPγS Functional Assays
-
2.1.3 cAMP Assays and cGMP Assays
-
2.1.4 β-Arrestin Functional Assays
-
2.1.5 Reporter Gene Assays
-
2.1.6 Other Assay Types
-
-
2.2 By Application
-
2.2.1 Cardiovascular System
-
2.2.2 Central Nervous System (CNS)
-
2.2.3 Oncology
-
2.2.4 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global G-Protein Coupled Receptors (GPCR) Market Size FAQs
How big is the Global G-Protein Coupled Receptors (GPCR) Market?
The Global G-Protein Coupled Receptors (GPCR) Market size is expected to reach USD 6.11 billion in 2024 and grow at a CAGR of 7.01% to reach USD 8.58 billion by 2029.
What is the current Global G-Protein Coupled Receptors (GPCR) Market size?
In 2024, the Global G-Protein Coupled Receptors (GPCR) Market size is expected to reach USD 6.11 billion.